ImmunityBio
IBRX
IBRX
47 hedge funds and large institutions have $21.8M invested in ImmunityBio in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
70% less call options, than puts
Call options by funds: $94K | Put options by funds: $309K
Holders
47
Holding in Top 10
–
Calls
$94K
Puts
$309K
Top Buyers
| 1 | +$1.21M | |
| 2 | +$527K | |
| 3 | +$504K | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$480K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$412K |
Top Sellers
| 1 | -$600K | |
| 2 | -$557K | |
| 3 | -$414K | |
| 4 |
OC
Oppenheimer & Co
New York
|
-$64.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$58K |